Company introduction – Cyclolab Cyclodextrin Research and Development Ltd

CycloLab Cyclodextrin Research and Development Ltd. is a private SME with the focus on cyclodextrin research and development for over 30 years. We are working in the fields of pharmaceutical, cosmetic and food industry, agrochemical, environmental and analytical applications of cyclodextrins.
CycloLab has four main activities:
1. We produce Sulfobutylether Beta-Cyclodextrin (SBECD, Dexolve™) in multiple ton scale annually under cGMP conditions based on an FDA-approved Drug Master File. This is a potent general solubilizer and stabilizer excipient, compatible with any kinds of administration forms.
2. CycloLab operates as a CRO for cyclodextrin related services including:
i) development of products (pharma, cosmetic, food, agricultural industries) – formulation development, optimization, characterization, in vitro bioequivalence studies, etc.
ii) offering custom synthesis of cyclodextrins, fine-tailored for certain guest molecules or purposes,
iii) performing (sub)pilot-scale cGMP compliant manufacturing of cyclodextrins to be used as APIs or excipients in clinical studies or cyclodextrin enabled formulations for the same purpose that are not available in suitable grades globally
iv) all analytical tasks related to the above, under GMP (method development,validation, stability studies for formulation ingredients (APIs, cyclodextrins) and final products as well. In this aspect, we are deeply engaged with Sugammadex as well.
3. CycloLab offers the widest variety of cyclodextrins in various grades (pharma, standard, fine chemical) in a web shop system for various purposes (research, analytics, cell cultures, formulation studies, etc). Besides "regular" derivatives, we always develop something new and special, like maltooligomers, polymers or fluorescent-tagged products. Within the product list, several Sugammadex related compounds are included.
4. As an R&D company, we develop next generation proprietary cyclodextrins and explore potential applications as well. These are focused in several areas as evaluating cyclodextrins as excipients in new areas like protein stabilization and non-viral gene delivery, fermentation and enzymatic processes, serum free culture media, creating selective and targeted drug delivery systems and evaluation of cyclodextrins as API candidates for CNS diseases, infections and other conditions.

Related News
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News China import tax fine could cost AstraZeneca up to US$8 million
British-Swedish drugmaker AstraZeneca could find itself facing fines of up to US$8million in China due to suspected unpaid import taxes on breast cancer drug Enhertu.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance